LOGO.jpg
Interpace Announces Extension of LabCorp Agreement
February 24, 2020 06:55 ET | Interpace Biosciences, Inc.
 ThyGeNEXT and ThyraMIR Collaboration Extended for Another Two Years PARSIPPANY, NJ, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that its...
LOGO.jpg
Interpace Biosciences Announces Another Pricing improvement for its Thyroid Assay
February 11, 2020 06:55 ET | Interpace Biosciences, Inc.
Parsippany, NJ, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that the Center for Medicare and Medicaid Services (CMS) has modified the reimbursement...
LOGO.jpg
Interpace Biosciences Announces Addition to Board of Directors and Changes in Leadership
January 30, 2020 06:55 ET | Interpace Biosciences, Inc.
Ron Rocca, CEO of Exagen, appointed to BoardJames Early, CFO announces retirement; Fred Knechtel, formerly CFO of GENEWIZ, appointed as CFOJeff Salzman, formerly of CareDX, appointed VP of Managed...
LOGO.jpg
Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital and Ampersand Capital Partners
January 13, 2020 06:55 ET | Interpace Biosciences, Inc.
Reverse Stock Split Planned Concurrent with Closing Investment expected to support achieving cash flow break-even and accelerate Interpace’s growth plans and acquisition strategy Parsippany,...
LOGO.jpg
Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN® after Ablation of Dysplastic Barrett’s Esophagus
January 06, 2020 06:55 ET | Interpace Biosciences, Inc.
Parsippany, NJ, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subsidiary,...
LOGO.jpg
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®
December 17, 2019 06:55 ET | Interpace Biosciences, Inc.
Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage...
LOGO.jpg
Interpace Biosciences Expands Strategic Partnership Activities with Genecast Biotechnology in China
December 05, 2019 06:55 ET | Interpace Biosciences, Inc.
Further Strengthens Business Development Team with Key Hire PARSIPPANY, N.J., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Interpace Bioscience’s subsidiary, Interpace Pharma Solutions today announced...
Logo.png
Interpace Biosciences Launches New Corporate Website
December 02, 2019 06:55 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (IDXG) announced today that it is launching its new corporate website, “Interpace.com”. Now both the Diagnostics and...
Logo.png
Interpace Diagnostics Changes Name to Interpace Biosciences; Announces Plans for Next Phase of Growth and Third Quarter 2019 Financial Results
November 13, 2019 16:40 ET | Interpace Biosciences, Inc.
Third Quarter Revenue Grew 34% Over the Prior Year’s Quarter and 25% Year to Date Acquired BioPharma Business in Partnership with Ampersand Diagnostic Test Volume Grew 16% for the Quarter and...
Logo.png
Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019
November 12, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET....